Research Grants 16/07367-5 - Mitocôndrias, Genes bcl-2 - BV FAPESP
Advanced search
Start date
Betweenand

Investigation of Phenothiazine-Induced Cell Death Mechanisms In Tumor Cells: Changes in Gene Expression, Role of Bcl-2 Family Proteins, and ER Stress

Abstract

Literature data have shown that psycotropic drugs derived from phenothiazines present antitumor activity. Working with isolated rat liver mitochondria, we previously showed that phenothiazine derivatives induced the mitochondrial permeability transition associated with cytochrome c release. After, we established the cytotoxic potential of different phenothiazine derivatives and determined the structural requirements for the induction of cell death by these drugs. Additionally, we proposed that mitochondrial permeabilization process plays a central role in thioridazine-induced cell death. In leukemia cells, the cell death induced by phenothiazines is a complex process with involvement of apoptosis and autophagy pathways, and our preliminary results show its modulation by Bcl-2 family proteins. Thus, the aim of this project is to investigate the molecular mechanisms of thioridazine-induced cell death in leukemic cells, particularly evaluating the role of Bcl-2 family proteins, the changes in gene expression of cell death-related pathways and the involvement of endoplasmic reticulum stress. Also, the antitumor effect of thioridazine in vivo will be evaluated. A quantitative PCR array with selected genes from apoptosis, autophagy and necrosis pathways will be performed to screen the possible targets of thioridazine. Also, it will be investigated the alterations in the amount of Bcl-2 expressed proteins, including the pro and anti-apoptotic members (BCL-2, BCL-XL, MCL-1, BAX, BAK, BID, BAD, PUMA and NOXA) and other proteins that interact with this family (Beclin), using specific monoclonal antibodies by western blotting or flow cytometry. Also, disruption of calcium homeostasis and endoplasmic reticulum stress response induced by thioridazine, as well as their modulation by Bcl-2 proteins, will be also studied. It was expected that these results will contribute not only for a better comprehension of the mechanisms of cell death in tumor cells, but also to the discovery of new therapeutic targets and drugs to be used in the antitumor chemotherapy. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (10)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
FERRAZ, LETICIA S.; WATASHI, CAROLINA M.; COLTURATO-KIDO, CARINA; PELEGRINO, MILENA T.; PAREDES-GAMERO, EDGAR J.; WELLER, RICHARD B.; SEABRA, AMEDEA B.; RODRIGUES, TIAGO. Antitumor Potential of S-Nitrosothiol-Containing Polymeric Nanoparticles against Melanoma. MOLECULAR PHARMACEUTICS, v. 15, n. 3, SI, p. 1160-1168, . (12/12247-8, 16/07367-5)
DO CARMO, ALINE LAGOEIRO; BETTANIN, FERNANDA; ALMEIDA, MICHELL ALMEIDA; PANTALEAO, SIMONE QUEIROZ; RODRIGUES, TIAGO; HOMEM-DE-MELLO, PAULA; HONORIO, KATHIA MARIA. Competition Between Phenothiazines and BH3 Peptide for the Binding Site of the Antiapoptotic BCL-2 Protein. FRONTIERS IN CHEMISTRY, v. 8, . (06/00995-9, 16/07367-5, 17/23416-9, 16/24524-7, 17/10118-0)
MEDEIROS, HYLLANA C. D.; COLTURATO-KIDO, CARINA; FERRAZ, LETICIA S.; COSTA, CLAUDIA A.; MORAES, VIVIAN W. R.; PAREDES-GAMERO, EDGAR JULIAN; TERSARIOL, IVARNE L. S.; RODRIGUES, TIAGO. AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia. Chemico-Biological Interactions, v. 315, . (16/07367-5, 12/12247-8)
MORAES, VIVIAN W. R.; SANTOS, VIVIAN M.; SUAREZ, ELOAH R.; FERRAZ, LETICIA S.; LOPES, RAYSSA DE MELLO; MOGNOL, GIULIANA P.; CAMPEIRO, JOANA D.; MACHADO-NETO, JOAO A.; NASCIMENTO, FABIO D.; HAYASHI, MIRIAN A. F.; et al. Targeting Ca2+ and Mitochondrial Homeostasis by Antipsychotic Thioridazine in Leukemia Cells. LIFE-BASEL, v. 12, n. 10, p. 20-pg., . (20/01107-7, 16/07367-5, 18/25747-5, 06/00995-9, 17/02413-1, 21/11606-3)
FERRAZ, LETICIA S.; WATASHI, CAROLINA M.; COLTURATO-KIDO, CARINA; PELEGRINO, MILENA T.; PAREDES-GAMERO, EDGAR J.; WELLER, RICHARD B.; SEABRA, AMEDEA B.; RODRIGUES, TIAGO. Antitumor Potential of S-Nitrosothiol-Containing Polymeric Nanoparticles against Melanoma. MOLECULAR PHARMACEUTICS, v. 15, n. 3, p. 9-pg., . (16/07367-5, 12/12247-8)
COLTURATO-KIDO, CARINA; LOPES, RAYSSA M.; MEDEIROS, HYLLANA C. D.; COSTA, CLAUDIA A.; PRADO-SOUZA, LAURA E. L.; FERRAZ, LETICIA S.; RODRIGUES, TIAGO. nhibition of Autophagy Enhances the Antitumor Effect of Thioridazine in Acute Lymphoblastic Leukemia Cell. LIFE-BASEL, v. 11, n. 4, . (16/07367-5, 18/25747-5)
DO CARMO, ALINE LAGOEIRO; BETTANIN, FERNANDA; ALMEIDA, MICHELL ALMEIDA; PANTALEAO, SIMONE QUEIROZ; RODRIGUES, TIAGO; HOMEM-DE-MELLO, PAULA; HONORIO, KATHIA MARIA. Competition Between Phenothiazines and BH3 Peptide for the Binding Site of the Antiapoptotic BCL-2 Protein. RONTIERS IN CHEMISTR, v. 8, p. 13-pg., . (17/23416-9, 16/07367-5, 17/10118-0, 06/00995-9, 16/24524-7)
ESTEVES, GABRIELA NOHEMI NUNEZ; FERRAZ, LETICIA SILVA; ALVAREZ, MARCELA MACIEL PALACIO; DA COSTA, CLAUDIA ALVES; LOPES, RAYSSA DE MELLO; TERSARIOL, IVARNE LUIS DOS SANTOS; RODRIGUES, TIAGO. BRAF and NRAS mutated melanoma: Different Ca2+ responses, Na+/Ca2+ exchanger expression, and sensitivity to inhibitors. Cell Calcium, v. 90, . (18/25747-5, 16/07367-5, 15/03964-6)
COLTURATO-KIDO, CARINA; LOPES, RAYSSA M.; MEDEIROS, HYLLANA C. D.; COSTA, CLAUDIA A.; PRADO-SOUZA, LAURA E. L.; FERRAZ, LETICIA S.; RODRIGUES, TIAGO. Inhibition of Autophagy Enhances the Antitumor Effect of Thioridazine in Acute Lymphoblastic Leukemia Cells. LIFE-BASEL, v. 11, n. 4, p. 14-pg., . (16/07367-5, 18/25747-5)
RODRIGUES, TIAGO; NUNEZ ESTEVEZ, GABRIELA NOHEMI; DOS SANTOS TERSARIOL, IVARNE LUIS. Na+/Ca2+ exchangers: Unexploited opportunities for cancer therapy?. Biochemical Pharmacology, v. 163, p. 357-361, . (15/03964-6, 16/07367-5)